Blood Test (First Visit Only) A blood test is necessary before starting treatment to understand your initial body condition and treatment progress
Schedule regular follow-up appointments to assess progress and make adjustments as needed
While semaglutide will remain under patent in many regions until the early 2030s, the first generic versions are expected to launch in India imminently, with additional market entries anticipated in China, Canada, Brazil, Turkey, and South Africa in the months that follow
Lixisenatide for type 2 diabetes mellitus patients inadequately controlled on oral antidiabetic drugs: a mixed-treatment comparison meta-analysis and cost-utility analysis
This distinction is important because pulse timing, amplitude, and inter-burst recovery intervals each influence receptor responsiveness and downstream signaling behavior